Literature DB >> 17102595

EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues.

Qingyu Zhou1, Yin Bun Cheung, Srinivasa Rao Jada, Wan Teck Lim, Wen-Lin Kuo, Joe W Gray, Ann S G Lee, Balram Chowbay.   

Abstract

AIM: The purpose of this study was to test the hypothesis if longer CA dinucleotide repeats are more common in the Asian population and also to gain insights into the interplay between the CA dinucleotide repeats and the frequencies of EGFR gene expression and amplifications as this might have therapeutic implications with regards to treatment with tyrosine kinase inhibitors.
MATERIALS AND METHODS: The EGFR intron 1 polymorphism was analysed in three distinct healthy Asian subjects, namely, Chinese (N = 96), Malays (N = 98) and Indians (N = 100). Comparative genomic hybridisation was performed to investigate for changes in DNA copy number in relation to the polymorphic CA dinucleotide repeats in breast tumor tissues (N = 22).
RESULTS: The frequency of short alleles with 14 and 15 CA repeats were most common in the Asian populations and significantly higher than those reported for Caucasians. The frequency of 20 CA repeats was 5%, almost 13-fold lower than previous reports. EGFR amplifications were detected in 23% and 11% of breast tumor tissues harboring short and long CA repeats, respectively.
CONCLUSION: Our results show that the frequency of alleles encoding for short CA dinucleotide repeats is common in Asian populations. EGFR expression and amplification levels were also higher in Asian breast tumor tissues with short CA dinucleotide repeats. These findings suggest that the EGFR intron 1 polymorphism may influence response to treatment with tyrosine kinase inhibitors in breast cancer patients and further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102595     DOI: 10.4161/cbt.5.11.3457

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  6 in total

1.  Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Authors:  Ranbir Chander Sobti; Marjan Askari; Mohsen Nikbakht; Neha Singh; Suresh C Sharma; Abayneh Munshea Abitew
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

2.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.

Authors:  Yogesh K Vashist; Florian Trump; Florian Gebauer; Asad Kutup; Cenap Güngör; Viacheslav Kalinin; Rather Muddasar; Eik Vettorazzi; Emre F Yekebas; Burkhard Brandt; Klaus Pantel; Jakob R Izbicki
Journal:  Target Oncol       Date:  2013-02-02       Impact factor: 4.493

4.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

5.  The genetic and epigenetic association of LDL Receptor Related Protein 1B (LRP1B) gene with childhood obesity.

Authors:  Suman Lee
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

6.  Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.

Authors:  Marcelo Sobral Leite; Letícia Carlos Giacomin; Diogo Nascimento Piranda; Juliana Simões Festa-Vasconcellos; Vanessa Indio-do-Brasil; Sérgio Koifman; Rodrigo Soares de Moura-Neto; Marcelo Alex de Carvalho; Rosane Vianna-Jorge
Journal:  BMC Cancer       Date:  2014-03-14       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.